Publications

467 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis

The National Health Care Institute has completed its assessment whether siponimod (Mayzent®) is interchangeable with a product ...

Report | 16-11-2020
Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

The National Health Care Institute has completed its assessment whether venetoclax (Venclyxto®) in combination with obinutuzumab ...

Report | 16-11-2020
GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia

The National Health Care Institute has completed its assessment whether glucagon nasal powder (Baqsimi®) for the treatment of ...

Report | 05-11-2020
GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)

The National Health Care Institute has completed its assessment whether ozanimod (Zeposia®) for the treatment of adult patients ...

Report | 28-10-2020
GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia

The National Health Care Institute has completed its assessment whether amisulpride (Aktiprol®) can be included in the GVS. ...

Report | 21-10-2020
Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder

The National Health Care Institute has completed its assessment whether esketamine nasal spray (Spravato®) can be included in the ...

Report | 30-09-2020
Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage

The National Health Care Institute has completed its assessment whether trastuzumab-emtansine (Kadcyla®) can be included in the ...

Report | 24-09-2020
Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients

The National Health Care Institute has completed its assessment whether Indacaterol/glycopyrronium/mometasone (Enerzair® ...

Report | 24-09-2020
Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years and older

The National Health Care Institute has completed its assessment whether indacaterol acetate/mometasone furoate (Atectura® ...

Report | 24-09-2020
Osimertinib (Tagrisso®) for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) with an epidermal growth factor receptor (EGFR) mutation (reassessment)

The Minister of Medical Care has requested the National Health Care Institute to reassess whether osimertinib (Tagrisso®) for the ...

Report | 21-09-2020

Publications

467 publications

GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis

Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia

GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)

GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia

Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder

Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage

Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients

Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years and older

Osimertinib (Tagrisso®) for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) with an epidermal growth factor receptor (EGFR) mutation (reassessment)

Go to